Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Amphenol
APH
|
$115M |
| 2 |
Microsoft
MSFT
|
$112M |
| 3 |
Ferguson
FERG
|
$104M |
| 4 |
Amazon
AMZN
|
$101M |
| 5 |
Apple
AAPL
|
$98.3M |
Top Sells
| 1 |
TIF
Tiffany & Co.
TIF
|
$96.7M |
| 2 |
DuPont de Nemours
DD
|
$52.5M |
| 3 |
CXO
CONCHO RESOURCES INC.
CXO
|
$43.4M |
| 4 |
AvalonBay Communities
AVB
|
$38.1M |
| 5 |
Equity Residential
EQR
|
$22.8M |
Sector Composition
| 1 | Technology | 25.7% |
| 2 | Healthcare | 14.14% |
| 3 | Consumer Discretionary | 13.72% |
| 4 | Communication Services | 10.9% |
| 5 | Industrials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2426
Cue Biopharma
CUE
$60M
| $676K | ﹤0.01% | 55,400 +2,000 | +4% | +$24.4K |
|
2427
RPC Inc
RES
$1.05B
| $664K | ﹤0.01% | 122,900 +3,200 | +3% | +$17.3K |
|
2428
Zynex
ZYXI
$49.7M
| $660K | ﹤0.01% | 43,200 | – | – |
|
2429
Citizens
CIA
$266M
| $653K | ﹤0.01% | 112,700 | – | – |
|
2430
Applied Therapeutics
APLT
$71M
| $649K | ﹤0.01% | 34,600 +4,200 | +14% | +$78.8K |
|
2431
Avidity Biosciences
RNA
$5.99B
| $648K | ﹤0.01% | 29,700 | – | – |
|
2432
SoundThinking
SSTI
$163M
| $645K | ﹤0.01% | 18,400 +700 | +4% | +$24.5K |
|
|
CASA
2433
DELISTED
Casa Systems, Inc. Common Stock
CASA
| $641K | ﹤0.01% | 67,300 | – | – |
|
2434
Repare Therapeutics
RPTX
$71.7M
| $638K | ﹤0.01% | 20,800 | – | – |
|
2435
Heritage Insurance Holdings
HRTG
$706M
| $637K | ﹤0.01% | 57,500 | – | – |
|
2436
Lifecore Biomedical
LFCR
$285M
| $635K | ﹤0.01% | 59,900 | – | – |
|
|
CNBKA
2437
DELISTED
Century Bancorp Inc/Mass
CNBKA
| $625K | ﹤0.01% | 6,700 | – | – |
|
2438
Phathom Pharmaceuticals
PHAT
$864M
| $623K | ﹤0.01% | 16,600 +500 | +3% | +$18.8K |
|
2439
TORM
TRMD
$2.13B
| $619K | ﹤0.01% | 67,885 | – | – |
|
2440
Nkarta
NKTX
$151M
| $612K | ﹤0.01% | 18,600 +3,800 | +26% | +$125K |
|
|
AXDX
2441
DELISTED
Accelerate Diagnostics
AXDX
| $597K | ﹤0.01% | 71,700 +3,100 | +5% | +$25.8K |
|
2442
FLEX LNG
FLNG
$1.47B
| $595K | ﹤0.01% | 68,303 | – | – |
|
|
MMX
2443
DELISTED
Maverix Metals Inc. Common Shares
MMX
| $593K | ﹤0.01% | 113,015 +11,000 | +11% | +$57.7K |
|
2444
Black Diamond Therapeutics
BDTX
$157M
| $592K | ﹤0.01% | 24,400 | – | – |
|
2445
Rush Enterprises Class B
RUSHB
$4.52B
| $577K | ﹤0.01% | 12,800 | – | – |
|
2446
Crinetics Pharmaceuticals
CRNX
$2.92B
| $575K | ﹤0.01% | 37,600 +1,400 | +4% | +$21.4K |
|
2447
XBiotech
XBIT
$96.3M
| $573K | ﹤0.01% | 33,400 +1,200 | +4% | +$20.6K |
|
2448
Greif Class B
GEF.B
$2.65B
| $572K | ﹤0.01% | 10,000 | – | – |
|
|
ATNX
2449
DELISTED
Athenex, Inc. Common Stock
ATNX
| $550K | ﹤0.01% | 128,000 +3,300 | +3% | +$14.2K |
|
2450
Korro Bio
KRRO
$217M
| $549K | ﹤0.01% | 57,800 +700 | +1% | +$6.65K |
|